{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:52:37Z","timestamp":1781927557334,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1R01 GM127656"],"award-info":[{"award-number":["1R01 GM127656"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.drup.2026.101356","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:12:34Z","timestamp":1768263154000},"page":"101356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Novel quinoxaline-based survivin degraders overcome docetaxel-resistance in castration-resistant prostate cancer"],"prefix":"10.1016","volume":"85","author":[{"given":"Caoqinglong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunzhen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6060-2674","authenticated-orcid":false,"given":"Robert C.","family":"Peery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-9914","authenticated-orcid":false,"given":"Jian-Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101356_bib1","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/molecules28031376","article-title":"Survivin small molecules inhibitors: recent advances and challenges","volume":"28","author":"Albadari","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.drup.2026.101356_bib2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101356_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2026.101356_bib4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"10.1016\/j.drup.2026.101356_bib5","doi-asserted-by":"crossref","first-page":"22932","DOI":"10.1074\/jbc.274.33.22932","article-title":"Role of poly (ADP-ribose) polymerase (PARP) cleavage in apoptosis: caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells","volume":"274","author":"Boulares","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101356_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/2159-8290.CD-24-0263","article-title":"Survivin Promotes Stem Cell Competence for Skin Cancer Initiation","volume":"15","author":"Canato","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101356_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1097-2765(05)00020-1","article-title":"Crystal structure of human survivin reveals a bow tie\u2013shaped dimer with two unusual \u03b1-helical extensions","volume":"6","author":"Chantalat","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.drup.2026.101356_bib8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/sj.neo.7900091","article-title":"Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth","volume":"2","author":"Chen","year":"2000","journal-title":"Neoplasia"},{"key":"10.1016\/j.drup.2026.101356_bib9","first-page":"179","article-title":"Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter","volume":"3","author":"Cheng","year":"2012","journal-title":"Int J. Biochem Mol. Biol."},{"key":"10.1016\/j.drup.2026.101356_bib10","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1016\/j.bmcl.2013.07.034","article-title":"Design, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle","volume":"23","author":"Chettiar","year":"2013","journal-title":"Bioorg. Med Chem. Lett."},{"key":"10.1016\/j.drup.2026.101356_bib11","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/01.MP.0000073868.31297.B0","article-title":"Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis","volume":"16","author":"Cohen","year":"2003","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.drup.2026.101356_bib12","doi-asserted-by":"crossref","first-page":"16515","DOI":"10.1021\/acs.jmedchem.3c01130","article-title":"Small Molecule Inhibitors Targeting the \u201cUndruggable\u201d Survivin: The Past, Present, and Future from a Medicinal Chemist\u2019s Perspective","volume":"66","author":"Cui","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2026.101356_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108714","article-title":"Design, synthesis, and evaluation of quinoxaline-based survivin inhibitors for castration-resistant prostate cancer","volume":"163","author":"Cui","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.drup.2026.101356_bib14","doi-asserted-by":"crossref","first-page":"34087","DOI":"10.1074\/jbc.C400236200","article-title":"An IAP-IAP complex inhibits apoptosis","volume":"279","author":"Dohi","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101356_bib15","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/cdd.2008.6","article-title":"The mechanism of peptide-binding specificity of IAP BIR domains","volume":"15","author":"Eckelman","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.drup.2026.101356_bib16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s12010-014-1125-6","article-title":"Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine","volume":"174","author":"Ghanbari","year":"2014","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.drup.2026.101356_bib17","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drup.2026.101356_bib18","article-title":"Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple negative breast cancer","volume":"13","author":"Josephraj","year":"2026","journal-title":"Genes Dis."},{"key":"10.1016\/j.drup.2026.101356_bib19","first-page":"5071","article-title":"Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer","volume":"58","author":"Kawasaki","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101356_bib20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s13046-019-1362-1","article-title":"Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?","volume":"38","author":"Li","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101356_bib21","first-page":"326","article-title":"14-3-3\u03c3, the double-edged sword of human cancers","volume":"1","author":"Li","year":"2009","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.drup.2026.101356_bib22","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1021\/ci200212y","article-title":"Critical residue that promotes protein dimerization: A story of partially exposed Phe25 in 14-3-3\u03c3","volume":"51","author":"Liu","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.drup.2026.101356_bib23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","article-title":"Hallmarks of cancer stemness","volume":"31","author":"Loh","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drup.2026.101356_bib24","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.014479","article-title":"The 89-kDa PARP1 cleavage fragment serves as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis","volume":"296","author":"Mashimo","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101356_bib25","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s12094-022-03043-y","article-title":"siRNA and targeted delivery systems in breast cancer therapy","volume":"25","author":"Mirzaei","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.drup.2026.101356_bib26","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41416-020-01105-y","article-title":"Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer","volume":"123","author":"Mout","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101356_bib27","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101356_bib28","first-page":"2805","article-title":"A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy","volume":"60","author":"Olie","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101356_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116761","article-title":"A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells","volume":"65","author":"Peery","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drup.2026.101356_bib30","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1021\/acs.jmedchem.0c00475","article-title":"Synthesis and identification of a novel lead targeting survivin dimerization for proteasome-dependent degradation","volume":"63","author":"Peery","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2026.101356_bib31","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.drudis.2017.05.009","article-title":"Targeting survivin for therapeutic discovery: past, present, and future promises","volume":"22","author":"Peery","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drup.2026.101356_bib32","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/carcin\/bgh107","article-title":"Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo","volume":"25","author":"Pennati","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.drup.2026.101356_bib33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0214891","article-title":"Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis","volume":"109","author":"Pennati","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.drup.2026.101356_bib34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1158\/0008-5472.CAN-15-1874","article-title":"Effective targeting of the survivin dimerization interface with small-molecule inhibitors","volume":"76","author":"Qi","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101356_bib35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/mol.114.092544","article-title":"Reversible epigenetic regulation of 14-3-3sigma expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1","volume":"86","author":"Qin","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2026.101356_bib36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00066-002-1003-y","article-title":"High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection","volume":"178","author":"R\u00f6del","year":"2002","journal-title":"Strahlenther. und Onkol."},{"key":"10.1016\/j.drup.2026.101356_bib37","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/sj.onc.1203429","article-title":"Survivin initiates procaspase 3\/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death","volume":"19","author":"Suzuki","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101356_bib38","first-page":"5315","article-title":"IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs","volume":"58","author":"Tamm","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101356_bib39","first-page":"127","article-title":"Expression of survivin and its relationship to loss of apoptosis in breast carcinomas","volume":"6","author":"Tanaka","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101356_bib40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/2211536612666230915105323","article-title":"MicroRNAs Regulate Inhibitor of Apoptosis Proteins (IAPs) in Colorectal Cancer","volume":"12","author":"Tanzadehpanah","year":"2023","journal-title":"MicroRNA"},{"key":"10.1016\/j.drup.2026.101356_bib41","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/77929","article-title":"Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement","volume":"7","author":"Verdecia","year":"2000","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.drup.2026.101356_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddiscovery.2015.61","article-title":"Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2\u2013Akt axis","volume":"1","author":"Vinod","year":"2015","journal-title":"Cell death Discov."},{"key":"10.1016\/j.drup.2026.101356_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2018.02.045","article-title":"Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors","volume":"149","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drup.2026.101356_bib44","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s12015-020-09995-4","article-title":"Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics","volume":"16","author":"Warrier","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.drup.2026.101356_bib45","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.bmcl.2007.03.042","article-title":"Discovery of a novel small molecule binding site of human survivin","volume":"17","author":"Wendt","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drup.2026.101356_bib46","doi-asserted-by":"crossref","first-page":"19781","DOI":"10.1074\/jbc.M310785200","article-title":"Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2","volume":"279","author":"Xu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101356_bib47","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.onc.1208490","article-title":"Survivin mediates resistance to antiandrogen therapy in prostate cancer","volume":"24","author":"Zhang","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101356_bib48","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bbrc.2018.03.021","article-title":"Knockdown of survivin results in inhibition of epithelial to mesenchymal transition in retinal pigment epithelial cells by attenuating the TGFbeta pathway","volume":"498","author":"Zhang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2026.101356_bib49","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/1535-7163.MCT-19-0118","article-title":"Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor","volume":"18","author":"Zhao","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101356_bib50","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1242\/jcs.113.23.4363","article-title":"The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner","volume":"113","author":"Zhao","year":"2000","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.drup.2026.101356_bib51","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinforma."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:37:07Z","timestamp":1781926627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":51,"alternative-id":["S1368764626000075"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101356","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel quinoxaline-based survivin degraders overcome docetaxel-resistance in castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101356"}}